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ABSTRACT
A set of 18 Acinetobacter baumannii isolates,
collected prospectively in a Bulgarian hospital
during episodes of increased A. baumannii occur-
rence during 2000–2002, was investigated for
genotypic diversity and antibiotic susceptibility.
Four genotypes were identiﬁed by ampliﬁed
fragment length polymorphism genomic ﬁnger-
printing, one of which (type 1) accounted for 13
isolates, indicating that a speciﬁc strain was
predominant. The single isolate allocated to type
2 was identiﬁed to European clone I. All isolates
were resistant to multiple antibiotics, but most
retained susceptibility to tobramycin and colistin,
and all except one were susceptible to imipenem.
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Most reports of multiresistant endemic or epi-
demic Acinetobacter baumannii are from western
European countries, and information concerning
this organism in central and eastern Europe is
scarce. A. baumannii has been endemic in the
hospital of the Military Medical Academy
(MMA), Sophia, Bulgaria since the early 1990s.
The present report investigated a set of A. bau-
mannii isolates, collected prospectively in the
MMA hospital during 2000–2002, for genotypic
relatedness and susceptibility to antibiotics. The
aims of the study were to determine whether a
single strain predominated in the hospital during
the collection period, and whether the isolates
were related to clones I–III found in hospital
outbreaks in several other European countries
[1–3].
The MMA is a 500-bed university hospital for
military personnel and civilians. It is a referral
hospital that provides acute medical and surgical
care, but not for paediatrics, obstetrics and
burns patients. The hospital has two intensive
care units, i.e., a 20-bed medical unit and a 16-bed
surgical unit. Many patients admitted to the
surgical intensive care unit are emergency cases
with poly-trauma following car accidents or
gunshot wounds. The hospital employs an infec-
tion control doctor and an infection control nurse,
who both participate in the infection control
committee of the hospital. The occurrence of
multidrug-resistant Acinetobacter has increased
steadily since the early 1990s, with recurrent
clusters of cases, especially in the two intensive
care units [4]. Control measures during such
epidemic episodes usually include isolation of
patients, as well as disinfection of the environ-
ment and surgical instruments on wards. Antibi-
otics for treatment of patients with infections
caused by Acinetobacter spp. include imipenem,
and amikacin plus ampicillin–sulbactam.
In total, 18 multidrug-resistant isolates of
Acinetobacter spp. from 18 patients were investi-
gated (Table 1). These isolates were selected from
among 65 multidrug-resistant Acinetobacter iso-
lates recovered during documented episodes of
increased occurrence during 2000–2002. The iso-
lates were selected to represent presumptive
cases of cross-infection, based on their antibiotic
susceptibility proﬁle and their origin in time and
space. Most isolates were from multi-trauma
patients, i.e., a group susceptible to colonisation
with A. baumannii [5]. The organisms were iden-
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tiﬁed initially to the genus Acinetobacter using the
automated Mini API System with ID32 strips
(bioMe´rieux, Marcy l’Etoile, France), and were
then identiﬁed to the species level by ampliﬁed
ribosomal DNA restriction analysis [6] and
ampliﬁed fragment length polymorphism (AFLP)
ﬁngerprint analysis [7]. Electrophoretic fragment
separation and data capture were performed
with the ALF express instrument (Amersham
Biosciences, Roosendaal, The Netherlands). For
ﬁnal species identiﬁcation, the AFLP proﬁles
were grouped with those of strains of described
genomic species in the Leiden AFLP library with
BioNumerics software v.3.5 (Applied Maths,
St Martens-Latem, Belgium). Isolates grouping
at ‡50% similarity were considered to belong to
the same species [7], while those that clustered at
‡82% and ‡90% similarity were considered to
belong to the same clone or strain, respectively
[2,8].
All 18 isolates were identiﬁed as A. baumannii
by both ampliﬁed ribosomal DNA restriction
analysis and AFLP analysis. At a clustering level
of 90%, the dendrogram of the AFLP ﬁngerprints
comprised one cluster with 13 isolates (type 1),
including two isolates with one extra fragment of
c. 250 bp, one cluster with three isolates (type 4),
and two single isolates (type 2 and type 3) (Fig. 1,
Table 1). The linkage of the 13 type 1 isolates at
94% in one main cluster indicated that one
particular strain predominated among the iso-
lates. Isolate LUH8592 (type 2) was identiﬁed as
European clone I, as it clustered at >82% with
reference strains of this clone (data not shown),
but none of the other isolates corresponded to
European clones I–III [1–3].
All isolates were tested routinely for antimicro-
bial susceptibility using the ATB-PSE 5 strip of the
Mini API system (bioMe´rieux). Screening for
extended-spectrum b-lactamases (ESBLs) was
performed with the ATB-BLSE strip. Sixteen of
the 18 isolates were resistant or intermediately-
resistant to piperacillin, piperacillin–clavulanate,
ceftazidime, aztreonam, gentamicin, netilmycin,
fosfomycin, peﬂoxacin and ciprofoxacin, but most
isolates were susceptible to ticarcillin (n = 11),
tobramycin (n = 11), colistin (n = 15) and imipe-
nem (n = 17). Based on the MICs of expanded-
spectrum cephalosporins and use of the
ATB-BLSE strip, the isolates were considered to
be possible ESBL producers.
To further investigate susceptibilities, a sub-set
of six isolates that represented the different
genotypes identiﬁed (LUH8604, LUH8605,
LUH8600, LUH8599, LUH8592 and LUH8590;
Table 1) was tested by the Vitek 2 system (bio-
Me´rieux) with the AST-N020 card. Vitek-derived
MICs (mg ⁄L) were 8 to ‡32 for ampicillin–clavul-
anic acid, 16 to ‡64 for ceftazidime, 0.5 to 2 for
meropenem, £1 to ‡16 for tobramycin, and ‡4 for
ciproﬂoxacin. None of the isolates produced a
clavulanic acid-inhibited ESBL when tested by
reference methods [9], or a metallo-enzyme, and
the blaVEB and blaPER genes were not detected by
PCR. The contradictory results concerning ESBL
detection may be explained by the fact that the
Table 1. Data for Acinetobacter
baumannii isolates from recurrent
epidemic episodes in the Military
Medical Academy, Soﬁa, Bulgaria
during 2000–2002
Isolate Patient
Date of
isolation
(day/month/year) Warda Specimenb
Underlying
conditionc AFLP typed
LUH8587 LP 30 ⁄ 06 ⁄ 00 Surg. ICU SW Abd. abscess 1
LUH8588 AP 02 ⁄ 11 ⁄ 00 Surg. ICU CC Poly-trauma 1
LUH8589 MA 24 ⁄ 11 ⁄ 00 Surg. ICU BA Poly-trauma 1
LUH8590 KR 25 ⁄ 11 ⁄ 00 Surg. ICU BA Poly-trauma 1
LUH8591 VS 04 ⁄ 09 ⁄ 01 Traum. SW Trauma 1
LUH8592 LI 24 ⁄ 09 ⁄ 01 Surg. ICU UR Poly-trauma 2
LUH8595 NV 15 ⁄ 11 ⁄ 01 Surg. ICU BL Poly-trauma 1
LUH8597 LD 23 ⁄ 11 ⁄ 01 Surg. ICU BL Poly-trauma 1
LUH8598 RN 23 ⁄ 11 ⁄ 01 Surg. ICU BA Poly-trauma 1
LUH8599 AD 27 ⁄ 12 ⁄ 01 Surg. ICU BA Poly-trauma 4
LUH8600 VT 08 ⁄ 01 ⁄ 02 Uro. UR URP 4
LUH8601 PP 18 ⁄ 01 ⁄ 02 Haem. UR Myeloma 1
LUH8602 SS 31 ⁄ 01 ⁄ 02 Surg. ICU BA Contusio cerebri 1
LUH8603 EA 16 ⁄ 08 ⁄ 02 Surg. ICU UR.CATH. Poly-trauma 1
LUH8604 PJ 23 ⁄ 08 ⁄ 02 Surg. ICU SW Poly-trauma 1
LUH8605 AD 23 ⁄ 08 ⁄ 02 Surg. ICU SW Poly-trauma 3
LUH8606 BB 02 ⁄ 09 ⁄ 02 Med. ICU BA Insultus cerebri 4
LUH8607 AA 02 ⁄ 09 ⁄ 02 Med. ICU BA Insultus cerebri 3
aSurg., surgical; Traum., traumatology; Uro., urology; Haem., haematology, Med., medical.
bSW, surgical wound; CC, central catheter; BA, bronchial aspirate; UR, urine; BL, blood; UR.CATH., urine catheter.
cAbd., abdominal; URP, trans-urethral resection of prostate gland.
dAmpliﬁed fragment length polymorphism (AFLP) type as shown in the dendrogram of Fig. 1.
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ATB-BLSE strips contain sulbactam as an inhib-
itor, and this antibiotic has intrinsic activity
against acinetobacters [10]. For this reason, the
ATB-BLSE strip is not useful for detection of ESBL
activity in A. baumannii.
The present report indicates that several multi-
drug-resistant strains, as distinguished by AFLP
analysis, were present in the MMA during the
study period, with one strain being predominant.
Except for one isolate identiﬁed to European
clone I, none of the isolates belonged to the
widespread European clones I–III [1–3]. This
raises the question of whether the evolution to
antibiotic resistance has occurred in these organ-
isms independently from other A. baumannii
strains in Europe. Further to the present report
from Bulgaria, multidrug-resistant A. baumannii
isolates have been reported in other central ⁄
eastern European countries [2,8]. With the recent
expansion of the European Union, and the expec-
ted increase in travel between eastern and west-
ern Europe, it is important to establish systems for
monitoring the occurrence of multidrug-resistant
A. baumannii in the new EU member states.
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Fig. 1. Dendrogram showing cluster analysis of ampliﬁed
fragment length polymorphism (AFLP) ﬁngerprints for the
18 Acinetobacter baumannii isolates included in the study.
The dotted line at 90% marks the level above which
individual strains are delineated. Surg, surgical; ICU,
intensive care unit; UR, urine; BA, bronchial aspirate;
Traum, traumatology; Med, medical; Uro, urology.
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